Literature DB >> 35175553

Biological Functions and Clinical Prospects of Extracellular Non-Coding RNAs in Diabetic Cardiomyopathy: an Updated Review.

Zhongwei Yin1, Chen Chen2.   

Abstract

Diabetic cardiomyopathy (DCM) is one of the major causes of heart failure in diabetic patients. However, the pathogenesis of diabetic cardiomyopathy has not been fully elucidated. Diagnosis and therapeutic strategy of DCM is still challenging. Various non-coding RNAs (ncRNA) are implicated in the onset and progression of DCM. Interestingly, ncRNAs not only are regulators intracellularly, but also can exist and function in extracellular space. Recent evidences have demonstrated that extracellular ncRNAs play emerging roles in both intracardiac and inter-organ communication during the pathogenesis of DCM; thus, extracellular ncRNAs are attractive diagnostic biomarkers and potential therapeutic targets for DCM. This article will review the current knowledge of the roles of extracellular ncRNAs in DCM, especially focusing on their physio-pathological properties and perspectives of potential clinical translation for biomarkers and therapies. Recent evidences have demonstrated that extracellular ncRNA play emerging roles in both intracardiac and inter-organ communication involved in the pathogenesis of diabetic cardiomyopathy (DCM), thus shown as attractive diagnostic biomarkers and potential therapeutics for DCM. In the current review, we first summarize the progress regarding the paracrine role of extracellular ncRNA in DCM. miRNAs and circRNAs have been shown to mediate the communication among cardiomyocytes, endothelial cells, and vascular smooth muscle cells in the diabetic heart. Subsequently, we systematically describe that extracellular ncRNAs contribute to the crosstalk between the heart and other organs in the context of diabetes. Researches have indicated that miRNAs acted as hepatokines and adipokines to mediates the injure effect of distal organs on hearts. As for clinical application, extracellular ncRNAs are promising biomarker and have therapeutic potential. (Created with BioRender.com).
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarker; Diabetic cardiomyopathy; Extracellular vesicle; Non-coding RNA; Therapeutic potential

Mesh:

Substances:

Year:  2022        PMID: 35175553     DOI: 10.1007/s12265-022-10217-0

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   3.216


  46 in total

Review 1.  Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches.

Authors:  Julia Beermann; Maria-Teresa Piccoli; Janika Viereck; Thomas Thum
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

Review 2.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.

Authors:  Guanghong Jia; Michael A Hill; James R Sowers
Journal:  Circ Res       Date:  2018-02-16       Impact factor: 17.367

Review 3.  Clinical utility of circulating non-coding RNAs - an update.

Authors:  Simone Anfossi; Anna Babayan; Klaus Pantel; George A Calin
Journal:  Nat Rev Clin Oncol       Date:  2018-09       Impact factor: 66.675

Review 4.  Non-coding RNAs as drug targets.

Authors:  Masayuki Matsui; David R Corey
Journal:  Nat Rev Drug Discov       Date:  2016-07-22       Impact factor: 84.694

Review 5.  Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence.

Authors:  Yi Tan; Zhiguo Zhang; Chao Zheng; Kupper A Wintergerst; Bradley B Keller; Lu Cai
Journal:  Nat Rev Cardiol       Date:  2020-02-20       Impact factor: 32.419

Review 6.  The fusion of two worlds: non-coding RNAs and extracellular vesicles--diagnostic and therapeutic implications (Review).

Authors:  Yukie Sato-Kuwabara; Sonia A Melo; Fernando A Soares; George A Calin
Journal:  Int J Oncol       Date:  2014-10-17       Impact factor: 5.650

Review 7.  Extracellular vesicles in type 2 diabetes mellitus: key roles in pathogenesis, complications, and therapy.

Authors:  Yongwei Xiao; Lei Zheng; Xiaofeng Zou; Jigang Wang; Jianing Zhong; Tianyu Zhong
Journal:  J Extracell Vesicles       Date:  2019-06-14

Review 8.  Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology.

Authors:  Wei Hu; Cong Liu; Zhuo-Yue Bi; Qun Zhou; Han Zhang; Lin-Lin Li; Jian Zhang; Wei Zhu; Yang-Yi-Yan Song; Feng Zhang; Hui-Min Yang; Yong-Yi Bi; Qi-Qiang He; Gong-Jun Tan; Cheng-Cao Sun; De-Jia Li
Journal:  Mol Cancer       Date:  2020-06-05       Impact factor: 27.401

Review 9.  MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics.

Authors:  Daniel Jakubik; Alex Fitas; Ceren Eyileten; Joanna Jarosz-Popek; Anna Nowak; Pamela Czajka; Zofia Wicik; Harald Sourij; Jolanta M Siller-Matula; Salvatore De Rosa; Marek Postula
Journal:  Cardiovasc Diabetol       Date:  2021-02-27       Impact factor: 9.951

Review 10.  Non-coding RNAs in cardiovascular cell biology and atherosclerosis.

Authors:  Francesca Fasolo; Karina Di Gregoli; Lars Maegdefessel; Jason L Johnson
Journal:  Cardiovasc Res       Date:  2019-10-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.